MEMOTEXT(R) Personalized Adherence Interventions Incorporated into First-of-its-Kind Study Funded by Microsoft HealthVault Be Well Fund
BETHESDA, MD, Jan. 13 /PRNewswire/ - MEMOTEXT announced today that
"We believe this new interface will significantly improve medication adherence in patients with glaucoma," says Amos Adler, President of MEMOTEXT. "It is an honor to collaborate on this special grant, and we are confident this trial will demonstrate that MEMOTEXT's technology-driven adherence solutions can make a significant difference in the lives of patients managing various conditions."
Studies have shown that medication non-adherence costs North America more than $100 billion and 125,000 lives every year. Medication non-adherence impacts all levels of health management, including treatment effectiveness and unnecessary hospitalizations, and almost six percent of all hospital admissions are due to failed patient adherence. Research also indicates that 70% of prescriptions are never consumed and 20% of all new drug prescriptions are never filled for the first time - with adherence rates as low as 10-20% for some disease states.
Approximately 40% of glaucoma patients have difficulty taking their eye drops on a regular basis, resulting in poor care despite an appropriate physician diagnosis and treatment plan. With the Internet and mobile phones so prevalent in patients' lives, they offer new ways to customize a patient adherence regimen. The results of this study should demonstrate MEMOTEXT program's usefulness for glaucoma, as well as the many other chronic diseases where adherence is important.
"Adherence to glaucoma therapy is one of the largest barriers we face in achieving therapeutic success," said glaucoma specialist Donald Budenz, M.D., M.P.H., of the Bascom Palmer Eye Institute in Miami. "We have numerous effective medications to treat this disease, but if patients don't use them, they're not effective. Providing real-time reminders to improve adherence to therapy will be a major step forward in the treatment of chronic diseases such as glaucoma."
The Be Well Fund is designed to stimulate not-for-profit research and development across a broad range of health disciplines that have the potential to significantly improve health and wellness outcomes by seeding innovative avenues of research and exploring the potential for disruptive improvements to health management enabled by re-use and sharing of data among people, families, caregivers, doctors and facilities.
"The Be Well Fund winners share our vision of using the Internet to empower people to fully engage in managing their health and improving health outcomes," said David Cerino, general manager of the Health Solutions Group at Microsoft Corp. "We're excited to help these organizations turn their ideas into reality and to expand the capabilities and services available through HealthVault."
Microsoft received nearly 200 proposals from leading academic and health research organizations across the United States, making it one of the most successful Microsoft Research RFPs in the company's history. Based on the strong interest, Microsoft increased award funding from $3 million to $4.5 million to help bring these proposals to market.
About "The Impact of Automated Dosing Reminders on Medication Adherence using HealthVault" Trial
This clinical trial will be completed in 14 months and in three phases: software development, a clinical research study, and subsequent data analysis. 500 subjects will be recruited in the U.S. for the two-part study, which includes a cohort study to assess baseline adherence with glaucoma medications followed by a randomized, controlled trial of the adherence intervention. Approximately 100 subjects will be randomized to participate in the technology-based adherence intervention program. The results of the study will be presented in a peer-reviewed forum upon completion of the trial, which is expected to conclude in mid-2010.
About Glaucoma and Adherence
Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. By the year 2010, worldwide, the number is predicted to be 60 million. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.
MEMOTEXT is a specialized healthcare application service provider focused on providing medication adherence intervention solutions. With over 25 years of expertise in patient-stakeholder issues and the telecommunications industry, MEMOTEXT integrates behavior modification, patient education and live support into the everyday lives of patients. MEMOTEXT uses proven methodologies and customized solutions that support patient efforts to maintain health and lifestyle regimens and comply with prescribed treatment plans. For more information about MEMOTEXT visit www.memotext.com.
|SOURCE MEMOTEXT Personalized Adherence Solutions|
Copyright©2009 PR Newswire.
All rights reserved